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Abstract: (R,R)ZX-5 is a NO regulatory compound, which could significantly increase 
choroidal blood flow in New Zealand rabbit. The aim of this paper is to investigate the 
molecular mechanism of (R,R)ZX-5 promoting NO production. Besides this, we also 
investigated the antiangiogenic activity of (R,R)ZX-5. Analysis of Western blot showed 
that (R,R)ZX-5 up-regulated the expression of Akt, p-Akt (Thr473), eNOS and p-eNOS 
(Ser1177), down-regulated the expression of Cyclin D1 in human retinal endothelial cells 
and escalated the intracellular free Ca
2+ concentration. Additionally, (R,R)ZX-5 inhibited 
the growth of blood vessels in the chick chorioallantoic membrane model. It is concluded 
that (R,R)ZX-5 promotes choroidal blood flow through PI3K/Akt-eNOS and 
Akt-Ca
2+-eNOS pathways. Additionally, (R,R)ZX-5 can inhibit angiogenesis.   
Keywords:  (R,R)ZX-5; age-related macular degeneration; choroidal neovascularization; 
signal pathways; angiogenesis 
 




Age-related macular degeneration (AMD) is an eye condition that leads to the deterioration of the 
center of the retina, called the macula, leading to loss of central vision. AMD is the fastest growing 
form of macular degeneration, and is the number one cause of severe vision loss and legal blindness in 
adults over 60 years of age in the U.S. There are two types of AMD—“dry” and “wet”. During the 
development of dry AMD, which is also known as non-neovascular AMD, cellular debris called drusen 
accumulates, and retinal pigment epithelial and choriocapillary atrophy. Wet AMD, also known as 
neovascular AMD, is more severe than dry AMD. Choroidal neovascularization (CNV) is the creation 
of new blood vessels in the choroids layer of the eye. During the process of Wet AMD, blood vessels 
grow from the choroid behind the retina. Wet AMD affects 10% of all patients, and accounts for more 
than 80% of vision loss in AMD [1, 2]. Decrease of the choroidal circulation is considered to be one of 
the reasons for CNV. It is important to improve and promote choroidal blood flow to alleviate AMD 
syndromes [3, 4]. 
Nitric oxide (NO) production by vascular endothelium is important in the regulation of blood flow. 
Reduced production of NO can adversely affect blood flow and ither vascular functions. NO is a key 
signaling messenger, which is synthesized in mammalian tissues by nitric oxide synthase (NOS). 
Endothelial nitric oxide synthase (eNOS) is the predominant NOS in vascular endothelial cells. Once 
NO is formed by eNOS, it plays an important role in blood flow and other vascular functions [3]. 
Moreover, pathological studies found that expression of eNOS was reduced in the choroidal blood 
vessels and choroidal vascular endothelial cells in patients with AMD [5]. Evidence indicated that the 
reduction of eNOS expression and nitric oxide (NO) production might contribute to the formation of AMD. 
In view of this, we designed and synthesized more than 200 NO regulatory compounds. These 
compounds were screened by Prof. George C. Y. Chiou [4] at Texas A & M University (Texas, USA) 
and found that compound (R,R)ZX-5 could significantly increase choroidal blood flow in New Zealand 
rabbit, but did not affect the blood flow in iris and ciliary body. (R,R)ZX-5 is the 
cis-1-phenyl-3-(3-methoxy-2-propoxy-5-[4-(3,4,5-trimethoxyphenyl)-1,3-dioxolane-2-yl]phenyl) thiourea. 
Moreover, the compound’s trans-isomer (S,S)ZX-5 is not able to promote choroidal blood flow in New 
Zealand white rabbit [4], suggesting that the promotion of choroidal blood flow is specific to 
cis-isomer (R,R)ZX-5.  
(R,R)ZX-5 has been proven to improve the choroidal blood flow without affecting the sclera and 
ciliary bodies in New Zealand white rabbits via increasing NO production [6]. In order to clarify the 
molecular mechanism of (R,R)ZX-5 promoting NO production, we investigated and found that the 
compound can increase the expression of eNOS and NO release in human umbilical vein endothelial 
cells [7]. Previous studies found that in addition to MAPK Kinase/ERKs, eNOS activity was also 
regulated by phosphoinositide 3-kinase/Akt and Ca
2+/Calm. So we investigated to see if ZX-5 
increases NO release through PI3K/Akt/eNOS/NO pathway or PI3K/Akt/Ca
2+/eNOS/NO pathway. 
In addition, inhibiting choroidal neovascularization (CNV) is an important treatment of AMD. So 
we studied the antiangiogenic activity of ZX-5. A useful model for studying angiogenesis and 
anti-angiogenesis in vivo is the chorioallantoic membrane (CAM) of the chicken embryo [2, 8]. The 
main advantages of CAM angiogenesis assays are their low cost, simplicity, reproducibility, and 
reliability [9]. Int. J. Mol. Sci. 2012, 13 
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2. Results and Discussion 
HREC was used in the current research for a few reasons; first, HRECs and HCECs (human 
choroidal endothelial cells) are both positive for the cell markers VEGFR1, VEGFR2, CD31, CD34 
and von Willebrand’s factor (vWF) [10]. Second, VEGF isoforms 121 and 165 were found to be 
equally potent in stimulating endothelial cell proliferation. And third, the anti-VEGF treatments 
ranibizumab and bevacizumab were effective in decreasing proliferation of HCEC and HREC. Finally, 
the results in this work indicated that (R,R)ZX-5 may also be applied in such animal models as 
proliferative diabetic retinopathy. 
2.1. Effect of ZX-5 on Akt, Phospho-Akt (Thr473), eNOS and Phospho-eNOS (Ser1177) Levels in HRECs 
To demonstrate the effect of ZX-5 on the PI3K/Akt pathway in HRECs, the expression of Akt, 
Phospho-Akt (Thr473), eNOS and Phospho-eNOS (Ser1177) were tested. Compared with 
DMSO-treated control cells, the protein expression level of Akt, Phospho-Akt (Thr473), eNOS and 
Phospho-eNOS (Ser1177) were up-regulated in a concentration dependent manner in (R,R)ZX-5-treated 
cells, whereas (S,S)ZX-5 down-regulated the expression of Akt and had no influence on the expression 
of phospho-Akt (Thr473), eNOS and p-eNOS (Ser1177) (Figures 1 and 2). 
Figure 1. Western blot analysis of Akt and p-Akt (Thr473) expression in HRECs after 
treatment. a, b: Lane 1, DMSO; Lane 2–4, (R,R)ZX-5 treatment at a dose of 7.5, 15,  
30 μg/mL; Lane 5–7, (S,S)ZX-5 treatment at a dose of 7.5, 15, 30 μg/mL (β-actin as the 
control). p-Akt473, Akt phosphorylation at threonine 473; T-Akt, total Akt. 
 
(a)  (b) 
Figure 2. Western blot analysis of eNOS and p-eNOS (ser1177) expression in HRECs after 
treatment. a, b: Lane 1, DMSO; Lane 2–4, treatment with (R,R)ZX-5 at a dose of 7.5, 15, 
30 μg/mL; Lane 5–7, treatment with (S,S)ZX-5 at a dose of 7.5, 15, 30 μg/mL (T-eNOS as 
the control).   
(a)  (b) Int. J. Mol. Sci. 2012, 13 
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PI3K/Akt signaling pathway is one of the important intracellular signal transduction pathways in 
response to the extracellular signals. The key effector molecule Akt in this signaling pathway exerts its 
effects in the cell by phosphorylating a variety of downstream substrates. The downstream targets of 
Akt include BAD, Caspase 9, FKHR, GLUTs, Ca
2+ and eNOS [11]. eNOS phosphorylation at Ser1177 
and Ser (Thr) 613 can enhance its activity which is affected by the PI3K/Akt. 
We think that (R,R)ZX-5 up-regulates eNOS expression and increases NO release through the 
activation of PI3K/Akt-eNOS pathway [12]. The signal pathway transduction are as follows [13]:  
First, PI3K is activated, which generates phosphatidylinositol-3,4,5-triphosphate (PI3P) and 
phosphatidylinositol-3,4-diphosphate (PI2P). PI3P recruits PDK1 and Akt serine/threonine kinase at 
the plasma membrane, which results in the phosphorylation and activation of Akt. Then p-Akt is 
released from cellular membranes and makes eNOS phosphorylated at Ser1177 and Ser (Thr) 613. 
Further, p-eNOS catalytes L-arginine to generate NO (Figure 3). 
Figure 3. (R,R)ZX-5 promotes choroidal blood flow through PI3K/Akt and Akt-Ca
2+-eNOS 
pathway and inhibits CNV through inhibiting angiogenesis. 
 
2.2. Effect of ZX-5 on Intracellular Free Ca
2+ Concentration in HRECs 
The intracellular free Ca
2+ concentration in the ZX-5 treated HRECs was detected. As (R,R)ZX-5 
up-regulated the protein expression level of Akt, Phospho-Akt (Thr473), eNOS and Phospho-eNOS 
(Ser1177) in a concentration range of 7.5 to 30 µg/mL, a concentration of 30 µg/mL was used in this 
experiment. The intracellular free Ca
2+ concentration was escalated significantly by (R,R)ZX-5 
treatment, but (S,S)ZX-5 did not change the intracellular free Ca
2+ concentration (Figure 4). Int. J. Mol. Sci. 2012, 13 
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Figure 4. Cell loading fluo-3 in Laser scanning confocal microscope. A1, A2: HRECs in 
the absence of fluo-3 and ZX-5 treatment. B1, B2: HRECs with fluo-3 and without ZX-5 
treatment. C1, C2: HRECs in the presence of fluo-3 after (S,S)ZX-5 treatment， at a dose of 
(S,S)ZX-5 is 30 μg/mL.  D1,  D2: HRECs in the presence of fluo-3 after (R,R)ZX-5 
treatment, at a dose of (R,R)ZX-5 is 30 μg/mL. A1, B1, C1, D1: at visible light; A2, B2, C2, 








D1 D2 Int. J. Mol. Sci. 2012, 13 
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Calcium is an important and ubiquitous intracellular messenger, controlling a diverse range of 
cellular processes, such as gene transcription, muscle contraction and cell proliferation [14]. In 
response to adequate stimuli, [Ca
2+]i (Intracellular Ca
2+ concentration) increases, oscillates and 
decreases, leading to the activation, modulation and termination of cell function. Numerous channels 
and pumps allow this particular cation to enter and exit cells and move between the cytosol and 
intracellular stores. Activation of NOS requires [Ca
2+], calmodulin, calcium-activated phosphatase, 
NADPH, and glutamate. eNOS (endothelial NOS) is constitutively expressed as latent enzymes and 
require a higher concentration of Ca
2+ for the enzyme activity [15]. 
We think that after p-Akt is released from cellular membranes and makes eNOS phosphorylated at 
Ser1177 and Ser (Thr) 613, p-Akt also increases [Ca
2+]i, which enhances the activity of eNOS further. 
In this way, p-eNOS catalytes L-arginine to generate more NO (Figure 3). 
2.3. Effect of ZX-5 on Cyclin D1 Level in HRECs 
To demonstrate the effect of ZX-5 on Cyclin D1 in HRECs, the expression of Cyclin D1 was 
assessed. Compared with DMSO-treated control cells, the protein expression level of Cyclin D1 was 
down-regulated in a concentration dependent manner in (R,R)ZX-5-treated cells, and (S,S)ZX-5 also 
down-regulated the expression of Cyclin D1 (Figure 5). 
Figure 5. Western blot analysis of Cyclin D1 expression in HRECs after treatment. Lane 1, 
DMSO; Lane 2–4, (R,R)ZX-5 treatment at a dose of 7.5, 15, 30 μg/mL; Lane 5–7, 
(S,S)ZX-5 treatment at a dose of 7.5, 15, 30 μg/mL (β-actin as the control).   
 
2.4. Inhibitory Effects of (R,R)ZX-5 on Angiogenesis in the CAM Model 
A CAM model was setup to evaluate the effect of (R,R)ZX-5 on angiogenesis. 48 h after drug 
administration into the chick embryos, medium and small blood vessels were counted within the  
15 mm radius from the center of the drug carrier plate. The effect of ZX-5 on angiogenesis has been 
shown in Figure 6. Compared with negative control groups, the angiogenesis were inhibited by 
(R,R)ZX-5 (inhibition ratios were 34.24%, 44.00% and 65.68% at 7.5, 15 and 30 μg/mL, respectively) 
in a concentration dependent manner. (S,S)ZX-5 had no effect on the angiogenesis (inhibition ratio was 
3.76% at 30 μg/mL) (Figure 7). 
Angiogenesis is a complex process, usually including vascular basement membrane degradation, 
endothelial cell activation, proliferation, migration, re-formation of new blood vessels and vascular 
networks. Cyclin D1 is cell cycle-related protein interacting with multiple other proteins which acts on 
G1 phase and promotes cells to enter S phase. We tested the effect of ZX-5 on Cyclin D1 expression 
on protein level in HREC. It was found that (R,R)ZX-5 can significantly inhibit angiogenesis and 
down-regulate the expression of Cyclin D1. Downregulation of Cyclin D1 expression may partially Int. J. Mol. Sci. 2012, 13 
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contribute to (R,R)ZX-5’s anti-angiogenic effect. (S,S)ZX-5 also down-regulated Cyclin D1 expression, 
but it had no influence on angiogenesis. 
Figure 6. Anti-angiogenic effect of ZX-5 on CAM. CAMs were treated with 0.1% DMSO, 
(R,R)-ZX-5 7.5 μg/mL, 15 μg/mL, 30 μg/mL, (S,S)-ZX-5 30 μg/mL, endostar for 48 h. 
 
Control endostar (S,S)-ZX-5 30 μg/mL 
 
(R,R)-ZX-5 7.5μg/mL (R,R)-ZX-5 15μg/mL (R,R)-ZX-5 30 μg/mL 
Figure 7. Inhibition rate of angiogenesis chick chorioallantonic membrane. The chick 
chorilallantonic membrane was treated with endostar(5 mg/mL), (R,R)-ZX-5(at a dose of 
ZX-5 was 30 μg/mL, 15 μg/mL, 7.5 μg/mL, respectively), (S,S)-ZX-5 (30 μg/mL), and 
physiological saline (0.1% DMSO). The data were presented as mean ± SD, ** p < 0.01  
(n = 5, five sections in each egg). 
 Int. J. Mol. Sci. 2012, 13 
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3. Experimental Section 
3.1. Cell Culture 
The human retinal endothelial cells line (HRECs) was purchased from the American Type Culture 
(ATCC, Shanghai, China) and maintained in T75 ﬂasks at 37 °C in an atmosphere of 5% CO2. Cells 
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen, USA) supplemented 
with 10% fetal bovine serum (FBS), and antibiotics (penicillin G 100 U/mL, streptomycin sulfate; 
Generay Biotech Co., Ltd., Shanghai, China). The cells were allowed to reach conﬂuence and then 
subcultured in 6-well plates at 8.0 × 10
5 cells/well until conﬂuent. To test the expression level of each 
protein, prepared cells were starved for 24 h in serum-free media before assay. 
3.2. Cell Treatment 
(R,R)ZX-5 and (S,S)ZX-5 were dissolved in Dimethyl sulfoxide (DMSO). 
HRECs incubated in DMEM medium were divided into 3 groups: group 1 treated with DMSO in 
serum-free media, group 2 treated with (R,R)ZX-5 (7.5, 15, 30 μg/mL) in serum-free media, group 3 
treated with (S,S)ZX-5 (7.5, 15, 30 μg/mL) in serum-free media. All cells were incubated for 24 h 
before western blot assay. 
3.3. Western Blot Analysis 
HRECs were seeded in 6-well culture plates with 8.0 × 10
5 cells per well and incubated for 24 h. 
Then the cells were treated by (R,R)ZX-5 or (S,S)ZX-5 for 24 h. The cells were harvested with 0.05% 
trypsin/0.53 mM EDTA (Hyclone, UT, USA), washed with phosphate-buffered saline (PBS), and 
resuspended in 100 μL of all Mammalian protein Extraction Reagent (Generay Biotech Co., Ltd. 
Shanghai, China). Concentrated proteins were separated on a 12% gel for the detection of Cyclin D1, 
Akt,  p-Akt (Thr473), a 8% gel for the detection of eNOS, p-eNOS (Ser1177), respectively. The 
separated proteins on the gel were transferred to PVDF membrane. Then the PVDF membrane 
(Millipore, MIT, USA) was incubated with a 1:1000 dilution of Cyclin D1, Akt, p-Akt (Thr473), eNOS, 
p-eNOS (Ser1177) and β-actin (Santa Cruz biotechnology, USA) antibodies. After incubation with the 
appropriate secondary antibodies (Multi Sciences Biotech Co., Ltd., Hang Zhou, China), blots were 
treated with the ECL reagents (Beyetime, Jiangsu province, China) and exposed to photographic film 
to detect protein expression. 
3.4. Measurement of Intracellular Free Ca
2+ Concentration by LSCM (Laser Scanning   
Confocal Microscope) 
Fluo-3/AM (Multi Sciences Biotech Co., Ltd., Hang Zhou, China) was used as an intracellular free 
Ca
2+ fluorescent probe. In short, after the treatment with 30 μg/mL (R,R)ZX-5 or (S,S)ZX-5 
respectively, cells were incubated with 3 µg Fluo-3/AM for 30 min at 37 °C (the final concentration of 
extracellular Fluo-3/AM was 3 µg/mL). Then the cells were washed 3 times with D-Hank’s solution to 
remove the extracellular Fluo-3/AM and the intracellular fluorescence was detected using a LSCM Int. J. Mol. Sci. 2012, 13 
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(Olympus Fv-1000, Olympus Corporation, Japan) with the excited light at a wavelength of 488 nm and 
the emission light at 525 nm. 
3.5. CAM Angiogenesis Assays 
The eggs which have been fertilized 6 days were used for the experiment and were incubated at 
70% of humidity and 37 °C. A window was opened on the top of each egg after 1 day incubation.  
The windows were covered with sterile tape and the eggs were returned to the incubator. After another 
1 day, the transparent tape was cut open and a drug carrier plate with a 15 mm diameter was placed in 
the chamber. Twenty microliters of each test reagent was added onto the plate. Test substances 
including (R,R)ZX-5 (the dose of ZX-5 was 7.5 μg/mL, 15 μg/mL, 30 μg/mL, respectively) and 
(S,S)ZX-5 (30 μg/mL). The physiological saline (0.1% DMSO) and endostatin (5 mg/mL) were used 
as negative and positive controls, respectively. Forty-eight hours after implantation of the filter paper 
disc, the pseudo-air chamber of chick embryos were opened and fixed in the fixative 
(formaldehyde-acetone, 1:1) for 5 min. The chick embryo was subsequently removed, and the CAM 
was carefully peeled off from the egg shell and laid out flat for photography. The number of 
medium-small blood vessels within a radius of 15 mm from the center of the carrier plate was counted.   
3.6. Statistical Analysis 
Data were presented as the mean ± SD. The statistical significance of the differences was 
determined by the method of analysis of variance (ANOVA) or unpaired two-tailed t-tests; a value of  
p < 0.05 was considered significant. 
4. Conclusions 
Previous research confirmed that (R,R)ZX-5 can improve choroidal blood flow via increasing NO 
production (4, 6). These effects were based on the up-regulation of eNOS expression through PI3K/Akt 
and Akt-Ca
2+-eNOS pathways. (R,R)ZX-5 also showed anti-angiogneic effect in a CAM assay. 
(R,R)ZX-5 is a promising candidate worthy of further investigation. 
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